- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04882111
ALIGN Intervention in Patients With Advanced Cancer Discharging to a SNF (ALIGN)
November 10, 2021 updated by: University of Colorado, Denver
ALIGN - A Palliative Care Social Work Intervention for Cancer Patients Discharging to a Skilled Nursing Facility
This is a single arm, pre-post, pilot study assessing the feasibility and acceptability of the ALIGN intervention in metastatic adult cancer patients discharging to local area SNFs.
Study Overview
Detailed Description
A novel approach for delivering high quality palliative care for cancer patients discharging to a skilled nursing facility (SNF) is critically needed.
This investigator plans to test a palliative care social work led intervention called ALIGN (Assessing and Listening to Individual Goals and Needs) that aims to define patient and caregiver goals, facilitate communication between patients and their care teams, and develop a patient-centered plan that accompanies the patient across all future health system transitions.
The central hypothesis is that implementation of ALIGN is feasible and acceptable for cancer patients and their caregivers and SNF staff.
Study Type
Interventional
Enrollment (Actual)
45
Phase
- Early Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Colorado
-
Aurora, Colorado, United States, 80045
- University of Colorado Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Stage II - IV solid tumor malignancy
- Discharging from an acute care hospital to a SNF in the metro Denver area
- Decisional capacity to consent
- English speaking
- (During COVID requirements) Either internet access through a computer, tablet, or smartphone OR cellular service with adequate allowance of cellular minutes to allow virtual visits (by participant's assessment)
Exclusion Criteria:
1. Discharging with hospice as their goal of care
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Discharged Cancer Patients
25 patients, adults ≥ 18, with stage II - IV solid tumor malignancy discharging from an acute care hospital to a SNF in the metro Denver area who have decisional capacity to consent and are English speaking.
|
The ALIGN intervention was developed by the Holding Group, an independent partnership of palliative care-trained social workers.
The intervention is theory driven, patient/caregiver centered, addresses palliative care and psychosocial issues, and integrates with health care teams.
Working in collaboration with KPCO and Dr. Stacy Fischer (primary mentor), the Holding Group tested the ALIGN intervention in the LTAC and SNF setting (Preliminary Studies).
The Holding Group will be the intervention personnel providing psychosocial care that targets communication, goal alignment, and caregiver support.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Subject retention
Time Frame: Two Years
|
This investigator anticipates the study to be feasible if enrollment and retention rates of patients and caregivers are within 60% of the goal and if, of those enrolled, 70% of patients and caregivers complete the intervention.
|
Two Years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Qualitative interviews of ALIGN participants
Time Frame: 1.5 years
|
Study staff will conduct individual semi-structured interviews with 15 patients and 15 caregivers who receive the ALIGN intervention.
|
1.5 years
|
Qualitative interviews of SNF staff
Time Frame: 1.5 years
|
Exit interviews will be conducted with 10 SNF front line staff (social worker, medical director, care manager, director of nursing) from SNF's that had 2 or more patients that received the intervention.
|
1.5 years
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Advanced Illness Coordinating Care Survey
Time Frame: Baseline and 60 days
|
A survey of satisfaction with care for patients and caregivers
|
Baseline and 60 days
|
Goal alignment measurement
Time Frame: Baseline and 60 days
|
Patients and providers will be asked a focus of treatment question ("Please select one of the options below that best describes your current focus of treatment") and asked to select from the following options: curative, life prolonging/rehabilitative, or comfort focused.
Patients and providers will be asked this question at the beginning and end of the study.
We are measuring whether there is increased congruence in the response between patient and providers at the end of the study.
If there is increased congruence this suggests that the ALIGN intervention is helping facilitate illness and prognostic understanding.
|
Baseline and 60 days
|
FACIT-Pal
Time Frame: Baseline and 60 days
|
This 39 item questionnaire measures four primary quality of life domains: physical well-being, social/family well-being, emotional well-being, functional well-being, and spiritual well-being.
Lower scores indicate lower quality of life.
|
Baseline and 60 days
|
Advance Care Planning documentation
Time Frame: Baseline and 60 days
|
Study staff will collect patient and caregiver reported outcomes (virtually by phone or Zoom) to help guide future estimations of sample size.
MDPOA, CPR directive, MOST are documents that communicate end of life wishes for patients and also who they would designate to make medical decisions on their behalf if they are unable to do so themselves.
We are measuring completion rates of these documents in patients who participate in the ALIGN intervention.
The more patients that have an MDPOA/CPR directives/MOST form completed after the intervention suggests that the ALIGN intervention helps people with advance care planning.
|
Baseline and 60 days
|
Decision Regret Scale
Time Frame: Baseline and 60 days
|
This 5 item scale measures distress or remorse after a health care decision.
The minimum score is 0 and the maximum score is 100.
A higher score indicates greater regret.
|
Baseline and 60 days
|
Caregiver Reaction Assessment
Time Frame: Baseline and 60 days
|
This is a 24 item instrument designed to measure the reactions of family members to caring for adults with a variety of illness.
The instrument focuses on five dimensions: caregiver's esteem, lack of family support, impact on finances, impact on schedule, and impact on health.
The minimum score is 0 and the maximum score is 24.
A higher score indicates greater caregiver burden.
|
Baseline and 60 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 28, 2020
Primary Completion (Actual)
November 1, 2021
Study Completion (Actual)
November 1, 2021
Study Registration Dates
First Submitted
November 3, 2020
First Submitted That Met QC Criteria
May 5, 2021
First Posted (Actual)
May 11, 2021
Study Record Updates
Last Update Posted (Actual)
November 11, 2021
Last Update Submitted That Met QC Criteria
November 10, 2021
Last Verified
November 1, 2021
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- 20-1656.cc
- P30CA046934 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cancer
-
University of Michigan Rogel Cancer CenterRecruitingCancer Liver | Cancer Brain | Cancer Head &Neck | Cancer PelvisUnited States
-
Cellworks Group Inc.RecruitingCancer | Relapsed Cancer | Refractory CancerUnited States
-
UNC Lineberger Comprehensive Cancer CenterHyundai Hope On WheelsRecruitingCancer | Pediatric Cancer | Survivorship | Cancer MetastaticUnited States
-
Vanderbilt-Ingram Cancer CenterNational Institutes of Health (NIH)Active, not recruitingAdvanced Cancer | Relapsed Cancer | Refractory CancerUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedStage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IV Gastric Cancer | Stage IVA Colorectal Cancer | Stage IVA Pancreatic Cancer | Stage IVB Colorectal Cancer | Stage IVB Pancreatic Cancer | Stage IIIA Gastric Cancer | Stage IIIB Gastric Cancer | Stage IIIC Gastric... and other conditionsUnited States
-
MiRXES Pte LtdRecruitingBreast Cancer | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Prostate Cancer | Thoracic Cancer | Liver CancerSingapore
-
Sidney Kimmel Cancer Center at Thomas Jefferson...CompletedStage I Breast Cancer | Stage I Uterine Corpus Cancer | Stage II Uterine Corpus Cancer | Stage III Uterine Corpus Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage... and other conditionsUnited States
-
Massachusetts General HospitalNational Comprehensive Cancer NetworkCompletedGastric Cancer | Pancreatic Cancer | Esophageal Cancer | Rectal Cancer | Colon Cancer | Hepatobiliary CancerUnited States
-
University of California, San FranciscoBristol-Myers Squibb; PfizerTerminatedStage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Metastatic Colorectal Adenocarcinoma | Metastatic Colon Adenocarcinoma | Metastatic Rectal Adenocarcinoma | Stage IIIA Colon Cancer | Stage IIIB Colon Cancer | Stage IIIC Colon Cancer | Stage IV Colon Cancer | Stage IV Rectal... and other conditionsUnited States
-
Johns Hopkins UniversityNational Cancer Institute (NCI); National Institute on Minority Health and...Enrolling by invitationCancer | Advanced Cancer | End Stage Cancer | MalignancyUnited States
Clinical Trials on ALIGN
-
Hasselt UniversityWithdrawn
-
University of Colorado, DenverKaiser PermanenteCompletedAdvanced Medical IllnessUnited States
-
Hospital Universitari Vall d'Hebron Research InstituteInstitut d'Investigació Biomèdica de Girona Dr. Josep Trueta; Hospital Universitari... and other collaboratorsCompletedFemale Stress Urinary IncontinenceSpain
-
Stanford UniversityVarian Medical SystemsTerminatedHead and Neck CancerUnited States
-
William Beaumont HospitalsTerminatedFibrosis, Liver | Cirrhosis, Liver | Steatohepatitis, Nonalcoholic | Fatty Liver DiseaseUnited States
-
Women's College HospitalTerminatedBipolar DepressionCanada
-
University of California, San DiegoNational Institute on Drug Abuse (NIDA); Open Society Foundations; UCSD Center... and other collaboratorsCompletedOccupational Needlestick InjuriesMexico
-
University of Turin, ItalyCompletedMaxillary Transverse Deficiency (MTD)Italy
-
Ochsner Health SystemProcter and GambleCompletedUrinary Tract Infections | Antibiotic Resistant Infection | Recurrent UTIUnited States
-
Stanford UniversityInternational Centre for Diarrhoeal Disease Research, Bangladesh; Thrasher...Completed